Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 857 | 125 | 728 |
| Samples | 391 | 65 | 324 |
| Peptides | 288 | 50 | 250 |
Function
MEP1B · Meprin A subunit beta
Meprins are multidomain zinc metalloproteases that are highly expressed in mammalian kidney and intestinal brush border membranes, and in leukocytes and certain cancer cells. They are involved in the hydrolysis of a variety of peptide and protein substrates, and have been implicated in cancer and intestinal inflammation. Mature meprins are oligomers of evolutionarily related, but separately encoded alpha and/or beta subunits. Homooligomers of alpha subunit are secreted, whereas, oligomers containing the beta subunit are plasma membrane-bound. This gene encodes the beta subunit. Targeted disruption of this gene in mice affects embryonic viability, renal gene expression profiles, and distribution of the membrane-associated alpha subunit in kidney and intestine. [provided by RefSeq, Oct 2011].
Isoforms & Proteins
2 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 284 amino-acid changes on canonical ENST00000269202 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in MEP1B · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in MEP1B – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 2/40 5% | 0/0 0% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 6/133 5% |
| Endometrial Carcinoma | 2/42 5% | 24/612 4% |
| Melanoma | 2/210 1% | 71/1899 4% |
| Hodgkins Lymphoma | 2/16 12% | 2/122 2% |
| Acute Myeloid Leukemia | 2/90 2% | 0/0 0% |
| Other Solid Cancers | 2/94 2% | 23/1515 2% |
| Squamous Cell Lung Carcinoma | 2/57 4% | 9/810 1% |
| Colorectal Carcinoma | 8/143 6% | 35/3239 1% |
| Non-Small Cell Lung Carcinoma | 11/304 4% | 8/1390 1% |
| Neuroendocrine Tumour | 8/154 5% | 0/577 0% |
| Gastric Carcinoma | 2/74 3% | 17/1809 1% |
| Ewings Sarcoma | 2/63 3% | 1/262 0% |
| Cervical Carcinoma | 0/35 0% | 4/422 1% |
| Ovarian Carcinoma | 2/109 2% | 7/998 1% |
| Small Cell Lung Carcinoma | 0/9 0% | 6/752 1% |
| Bladder Carcinoma | 0/58 0% | 8/956 1% |
| Other Sarcomas | 2/69 3% | 4/699 1% |
| Hepatocellular Carcinoma | 0/46 0% | 15/2210 1% |
| B-Cell Non-Hodgkins Lymphoma | 1/88 1% | 15/2534 1% |
| Plasma Cell Myeloma | 2/44 5% | 0/305 0% |
| Thyroid Gland Carcinoma | 0/45 0% | 9/1592 1% |
| Germ Cell Tumour | 0/25 0% | 1/169 1% |
| Esophageal Squamous Cell Carcinoma | 4/51 8% | 9/2550 0% |
| Glioma | 1/52 2% | 9/2127 0% |
| Mesothelioma | 0/62 0% | 1/165 1% |
| Burkitts Lymphoma | 1/32 3% | 0/196 0% |
| Head and Neck Carcinoma | 1/85 1% | 6/1574 0% |
| Kidney Carcinoma | 0/85 0% | 7/1862 0% |
| Biliary Tract Carcinoma | 0/54 0% | 3/950 0% |
Mutation Distribution
Where MEP1B is mutated · all tissues, split by cell line vs tissue
How many mutations in MEP1B were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 857 mutations in MEP1B
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|